BB1 Stock Overview
BlinkLab Limited focuses on the development and commercialization of intellectual property related to smartphone-neurobehavioral testing.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
BlinkLab Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.38 |
| 52 Week High | AU$0.33 |
| 52 Week Low | AU$0.23 |
| Beta | 0 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 41.51% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| BB1 | AU Healthcare Services | AU Market | |
|---|---|---|---|
| 7D | 36.4% | 3.0% | -1.3% |
| 1Y | n/a | 66.7% | 6.0% |
Return vs Industry: Insufficient data to determine how BB1 performed against the Australian Healthcare Services industry.
Return vs Market: Insufficient data to determine how BB1 performed against the Australian Market.
Price Volatility
| BB1 volatility | |
|---|---|
| BB1 Average Weekly Movement | n/a |
| Healthcare Services Industry Average Movement | 7.9% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in AU Market | 17.7% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: BB1's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine BB1's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | n/a | Hendrikus Boele | www.blinklab.org |
BlinkLab Limited focuses on the development and commercialization of intellectual property related to smartphone-neurobehavioral testing. The company’s smartphone-based application serves as a medical device to perform neurometric tests, such as eyeblink conditioning, prepulse inhibition of acoustic startle, and habituation of eye blink response that serve as biomarkers for neurological and psychiatric disorders. Its application records and uploads the neurometric test results to an online platform, where the data is analyzed using machine learning to aid in the diagnosis of autism spectrum disorder (ASD), attention deficit hyperactivity disorder (ADHD), schizophrenia, and other neurodevelopmental conditions.
BlinkLab Limited Fundamentals Summary
| BB1 fundamental statistics | |
|---|---|
| Market cap | AU$32.22m |
| Earnings (TTM) | -AU$483.10k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-77.0x
P/E RatioIs BB1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BB1 income statement (TTM) | |
|---|---|
| Revenue | AU$0 |
| Cost of Revenue | AU$106.90k |
| Gross Profit | -AU$106.89k |
| Other Expenses | AU$376.21k |
| Earnings | -AU$483.10k |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0049 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did BB1 perform over the long term?
See historical performance and comparison